OPKO Biologics Ltd. Market Research Report

Background

Company Overview

OPKO Biologics Ltd. is a clinical-stage biopharmaceutical company specializing in the development of next-generation, long-acting versions of therapeutic proteins and peptide drugs. Utilizing proprietary technologies such as Carboxyl Terminal Peptide (CTP) and reversible PEGylation, the company aims to enhance the efficacy and patient compliance of existing therapies. Established in 2013 as a wholly-owned subsidiary of OPKO Health, Inc., OPKO Biologics operates from state-of-the-art facilities in Kiryat Gat, Israel, which include integrated laboratories, a GLP Bioanalytical unit, CMC development labs, and a cGMP certified QC lab.

Mission and Vision

OPKO Biologics is committed to improving the quality of life for patients by advancing the development of innovative, long-acting biologic therapies. The company's vision is to become a leader in the biopharmaceutical industry by delivering high-quality, patient-centric solutions that address unmet medical needs.

Industry Significance

In the biopharmaceutical sector, the demand for long-acting therapies is growing due to their potential to improve patient adherence and outcomes. OPKO Biologics' focus on developing bio-better versions of existing therapeutic proteins positions it strategically to meet this demand and contribute significantly to the industry's evolution.

Key Strategic Focus

Core Objectives

Development of Long-Acting Therapies: Utilizing CTP and reversible PEGylation technologies to extend the half-life of therapeutic proteins and peptides.

Enhancement of Patient Compliance: Reducing the frequency of administration to improve patient adherence to treatment regimens.

Expansion of Therapeutic Indications: Broadening the application of long-acting biologics across various medical conditions.

Areas of Specialization

Protein and Peptide Drug Development: Focusing on the modification of existing proteins and peptides to create more effective and convenient treatments.

Biologics Manufacturing: Establishing robust processes for the production of biologic therapies, ensuring scalability and compliance with regulatory standards.

Key Technologies Utilized

CTP Technology: A platform that extends the half-life of therapeutic proteins by attaching a carboxyl terminal peptide.

Reversible PEGylation: A synthetic chemistry-based method for enhancing the pharmacokinetic properties of biologic drugs.

Primary Markets Targeted

Growth Hormone Deficiency: Developing long-acting growth hormone therapies for pediatric and adult patients.

Hemophilia: Creating extended-release Factor VIIa treatments for hemophilia patients.

Obesity and Metabolic Disorders: Collaborating on oral formulations for weight management and related conditions.

Financials and Funding

Funding History

As a subsidiary of OPKO Health, OPKO Biologics' funding is integrated within the parent company's financial structure. Specific details regarding total funds raised and recent funding rounds are not publicly disclosed.

Notable Investors

While individual investors in OPKO Biologics are not specified, OPKO Health's diverse portfolio includes investments in various early-stage companies developing novel technologies in areas such as molecular diagnostics, pharmaceuticals, and biologics.

Utilization of Capital

Capital is primarily allocated towards research and development activities, including the advancement of the company's pipeline candidates, enhancement of manufacturing capabilities, and expansion of clinical trials to support regulatory approvals.

Pipeline Development

Key Pipeline Candidates

hGH-CTP (Long-Acting Growth Hormone): A once-weekly human growth hormone injection for the treatment of growth failure in children and adults.

Factor VIIa-CTP: A longer-acting Factor VIIa drug for hemophilia patients.

OPK-88006: A proprietary long-acting oxyntomodulin analog for the treatment of obesity and metabolic disorders.

Stages of Development

hGH-CTP: Completed Phase 3 studies; partnered with Pfizer for commercialization.

Factor VIIa-CTP: Entering Phase 2a clinical trials.

OPK-88006: In preclinical development; collaboration with Entera Bio Ltd. initiated in 2023 to develop oral formulations.

Target Conditions

hGH-CTP: Growth hormone deficiency in children and adults.

Factor VIIa-CTP: Hemophilia.

OPK-88006: Obesity, metabolic disorders, and fibrotic conditions.

Anticipated Milestones

hGH-CTP: FDA approval and market launch in collaboration with Pfizer.

Factor VIIa-CTP: Completion of Phase 2a trials and progression to Phase 3.

OPK-88006: Filing of Investigational New Drug application with the FDA.

Technological Platform and Innovation

Proprietary Technologies

CTP Technology: Enhances the half-life of therapeutic proteins, reducing the frequency of administration.

Reversible PEGylation: Improves the pharmacokinetic properties of biologic drugs, enhancing their efficacy and patient compliance.

Significant Scientific Methods

Assays: Utilized for the characterization and quality control of biologic products.

Machine Learning Algorithms: Employed in the analysis of clinical trial data and optimization of drug development processes.

Leadership Team

Key Executives

Laura Moschcovich, PhD – General Manager: Joined OPKO Biologics in 2007; led the development of the purification process for MOD-4023 (CTP-growth hormone).

Ahuva Bar-Ilan, PhD – VP Preclinical and Clinical Pharmacology: Joined in 2006; responsible for preclinical proof of concept, pharmacology, and toxicology studies.

Sagit Pinto-Finkel, CPA, MBA – VP Finance: Joined in 2014; oversees all financial aspects of the clinical department.

Miri Gerzon-Zakar, M.Sc. – Senior Director, CMC: Joined in 2011; responsible for production development and manufacturing activities of peptide and protein-based drugs.

Dana Avraham, B.Sc, CQE – Senior QA Director: Joined in 2015; manages all QA activities, including regulatory inspections and quality standards.

Gabi Faibish, LLB, MBA – VP Operations and General Counsel: Joined in 2015; oversees legal, compliance, and privacy matters, and operations.

Competitor Profile

Market Insights and Dynamics

The global biopharmaceutical market is experiencing significant growth, with a projected valuation of $3.44 trillion by 2030. This expansion is driven by increasing demand for innovative therapies, including long-acting biologics. OPKO Biologics operates in a competitive landscape, contending with both established pharmaceutical companies and specialized biotech firms.

Competitor Analysis

Labcorp: A leading clinical laboratory offering a wide range of diagnostic services.

Quest Diagnostics: Provides comprehensive diagnostic testing services and has a significant market presence.

Amgen: A global biopharmaceutical company with a diverse portfolio, including biologic therapies.

Strategic Collaborations and Partnerships

In March 2025, OPKO Health and Entera Bio Ltd. entered into a collaboration to develop a once-daily oral treatment targeting obesity and related metabolic and fibrotic disorders. This partnership combines Entera's oral delivery technology with OPKO's GLP-1 agonist (OPK-88006), aiming to create an innovative oral alternative in the weight-loss drug market.

Operational Insights

OPKO Biologics differentiates itself through its proprietary technologies, such as CTP and reversible PEGylation, which enhance the efficacy and patient compliance of therapeutic proteins and peptides. The company's integrated facilities in Israel support a comprehensive approach to drug development, from research to manufacturing.

Strategic Opportunities and Future Directions

OPKO Biologics is well-positioned to capitalize on the growing demand for long-acting biologics. The company's strategic focus on innovative drug development, coupled with its recent collaborations, provides a solid foundation for future growth and market expansion.